Long-Term Monitoring & Staying Safe
At a Glance
Long-term care for ADAR-related HSP may include individualized heart ultrasounds, blood counts and liver and kidney tests during JAK inhibitor treatment, swallowing assessment, and an emergency plan for sudden movement decline, severe muscle contractions, infection, heart symptoms, or choking.
While the movement symptoms of ADAR-related HSP are often the most visible, this condition can affect other parts of the body. Because it is an immune-mediated disease, long-term care involves monitoring the heart, liver, and blood, especially if you are using specialized medications.
The Heart: Monitoring for Valve Changes
A specific risk reported in selected ADAR1 presentations (particularly severe biallelic AGS6 phenotypes) is the development of calcium deposits on the heart valves [1]. This is referred to as calcific valvular disease.
- What happens: Over time, the valves (usually the mitral and aortic valves) can become stiff (stenosis) or fail to close properly (regurgitation) [1][2]. This has been reported to begin in late childhood or early adolescence [1].
- Surveillance: Because this process can be “insidious”—meaning it happens slowly without obvious symptoms—doctors recommend discussing a baseline cardiology assessment and establishing an individualized schedule for echocardiograms (ultrasounds of the heart) to detect changes early [1].
- Outcome: If caught early, these changes can be managed, and in some cases, valve replacement surgery has led to favorable long-term outcomes [1].
Monitoring the Immune System and Blood Toxicity
If you are taking experimental JAK inhibitors (like ruxolitinib or baricitinib), your care team will require frequent blood tests to monitor for drug toxicity.
- Hematologic Monitoring: These drugs can lower your blood counts. Doctors watch closely for neutropenia (a dangerously low absolute neutrophil count, which drastically increases infection risk) and anemia (low red blood cells) [3][4].
- Liver and Kidney Health: Periodic tests of liver enzymes and kidney function are standard toxicity monitoring while on these medications [5][6].
- Infection Risk: You must be screened for latent infections like tuberculosis before starting these drugs [7].
Nutrition and Movement Tracking
- Swallowing (Dysphagia): Depending on the phenotype, some patients with this spectrum of disease develop difficulty swallowing [6]. This can lead to food or liquid entering the lungs (aspiration), which can cause pneumonia. Swallowing evaluation is particularly important when there are symptoms like coughing after meals, weight loss, or recurrent chest infections [8].
- Neurological Tracking: Your doctor may use tools like the Spastic Paraplegia Rating Scale (SPRS) during visits to objectively measure if muscle stiffness is stable or changing [9].
Red Flags: When to Seek Immediate Care
It is important to know the difference between a “routine” symptom and a situation that requires urgent medical attention.
Call Your Specialist Immediately (Same Day)
- New Involuntary Movements: Sudden onset of twisting or jerking that is not part of your normal baseline [10].
Go to the Emergency Room (ER) or Seek Urgent Assessment
- Sudden Motor Regression: A rapid loss of the ability to walk or sit that happens over a few days or weeks. This requires urgent assessment as it can signal infection, medication withdrawal, spinal cord disease, stroke, or a seizure [11][12].
- Status Dystonicus: This is a medical emergency where severe, painful muscle twisting or contractions do not stop. It can lead to exhaustion and life-threatening complications [10].
- Signs of Heart Failure: Seek care immediately for new, severe shortness of breath (especially when lying flat), sudden swelling in the legs/ankles, or fainting spells [1].
- Severe Infection: If you are on an immunomodulator and develop a high fever, severe lethargy, altered awareness, or rapid breathing [13][14].
- Aspiration/Choking: Any episode where you or your child cannot clear their airway, turns blue, or experiences severe choking [6].
- Baclofen Pump Failure: If you have an ITB pump and experience sudden rebound spasticity, confusion, or fever.
Medication Rules: Missed Doses
If you miss a dose of a JAK inhibitor, do not double a dose. Follow the prescription label exactly, and contact your prescriber or pharmacist for missed-dose, infection, surgery, or vaccination instructions [13].
By staying consistent with monitoring and knowing these warning signs, you and your medical team can act quickly to protect your long-term health.
Common questions in this guide
How are heart valve problems monitored in ADAR-related HSP?
What tests are needed if I take a JAK inhibitor for ADAR-related HSP?
What swallowing symptoms should prompt an evaluation?
When should a sudden change in movement lead to urgent care?
Which heart symptoms require immediate medical attention?
What should I do if I miss a JAK inhibitor dose?
What infection or choking signs are emergencies?
Get notified when new evidence is published on ADAR-related hereditary spastic paraplegia.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.
References
References (14)
- 1
Cardiac valve involvement in ADAR-related type I interferonopathy.
Crow Y, Keshavan N, Barbet JP, et al.
Journal of medical genetics 2020; (57(7)):475-478 doi:10.1136/jmedgenet-2019-106457.
PMID: 31772029 - 2
Case of Aicardi-Goutières syndrome diagnosed in adulthood on whole-genome sequencing.
Cobb L, Kumar J, Roy A, et al.
BMJ neurology open 2026; (8(2)):e001407 doi:10.1136/bmjno-2025-001407.
PMID: 42483269 - 3
Hematologic abnormalities in Aicardi Goutières Syndrome.
Adang LA, Gavazzi F, D'Aiello R, et al.
Molecular genetics and metabolism 2022; (136(4)):324-329 doi:10.1016/j.ymgme.2022.06.003.
PMID: 35786528 - 4
Aicardi-Goutières syndrome type 6: report of ADAR variant and clinical outcome after ruxolitinib treatment in the neonatal period.
Gabaldon-Albero A, Martin-Grau C, Marti-Masanet M, et al.
Pediatric rheumatology online journal 2024; (22(1)):110 doi:10.1186/s12969-024-01036-5.
PMID: 39732715 - 5
Hepatic Involvement in Aicardi-Goutières Syndrome.
Gavazzi F, Cross ZM, Woidill S, et al.
Neuropediatrics 2021; (52(6)):441-447 doi:10.1055/s-0040-1722673.
PMID: 33445189 - 6
Systemic complications of Aicardi Goutières syndrome using real-world data.
Peixoto de Barcelos I, Jan AK, Modesti N, et al.
Molecular genetics and metabolism 2024; (143(1-2)):108578 doi:10.1016/j.ymgme.2024.108578.
PMID: 39332260 - 7
Reactivation of Pulmonary Tuberculosis following Treatment of Myelofibrosis with Ruxolitinib.
Abidi MZ, Haque J, Varma P, et al.
Case reports in hematology 2016; (2016()):2389038 doi:10.1155/2016/2389038.
PMID: 27843657 - 8
Systematic analysis of genotype-phenotype variability in siblings with Aicardi Goutières Syndrome (AGS).
de Barcelos IP, Woidill S, Gavazzi F, et al.
Molecular genetics and metabolism 2024; (142(1)):108346 doi:10.1016/j.ymgme.2024.108346.
PMID: 38368708 - 9
Case report on novel mutation in SPAST gene in Polish family with spastic paraplegia.
Klimkowicz-Mrowiec A, Dziubek A, Sado M, et al.
BMC neurology 2019; (19(1)):322 doi:10.1186/s12883-019-1561-6.
PMID: 31837705 - 10
Movement disorders in ADAR1 disease: Insights from a comprehensive cohort.
Di Lazzaro G, Graziola F, Sancesario A, et al.
Parkinsonism & related disorders 2020; (79()):100-104 doi:10.1016/j.parkreldis.2020.08.039.
PMID: 32911246 - 11
Variable clinical phenotype in two siblings with Aicardi-Goutières syndrome type 6 and a novel mutation in the ADAR gene.
Schmelzer L, Smitka M, Wolf C, et al.
European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society 2018; (22(1)):186-189 doi:10.1016/j.ejpn.2017.11.003.
PMID: 29221912 - 12
Multi-dimensional Insight into the Coexistence of Pathogenic Genes for ADAR1 and TSC2: Careful Consideration is Essential for Interpretation of ADAR1 Variants.
Liu X, Lei M, Xue Y, et al.
Biochemical genetics 2024; (62(3)):1811-1826 doi:10.1007/s10528-023-10488-5.
PMID: 37740860 - 13
Severe ARDS due to Ruxolitinib discontinuation syndrome: case presentation and literature review.
Houthuys JF, Wilmer AP, Peetermans M, et al.
Heliyon 2022; (8(12)):e11782 doi:10.1016/j.heliyon.2022.e11782.
PMID: 36478803 - 14
The emerging safety profile of JAK inhibitors in rheumatic disease.
Winthrop KL
Nature reviews. Rheumatology 2017; (13(4)):234-243 doi:10.1038/nrrheum.2017.23.
PMID: 28250461
This page is for informational purposes only and does not constitute medical advice. Your neurology, cardiology, and prescribing teams should set your individualized monitoring schedule and emergency plan for ADAR-related HSP.